Moderna’s Cancer Vaccine Shows Promise | Business and Finance News

episode

Business News Today | 2 Min News | The Daily News Now! not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Business News Today | 2 Min News | The Daily News Now!

Japanese Capsule Hotels: Budget Solution for London Hybrid Workers 1 min · 20 Dec 2025

Russia's War Economy: Sustainable or Unsustainable? 2 min · 20 Dec 2025

All episodes from Business News Today | 2 Min News | The Daily News Now! →

Report any issue

Source

Recorded19 Aug 2026

Publisherfeeds.acast.com ↗

Handlerec:20066801

Show notes

Moderna and Merck just dropped a game-changing update on their personalized melanoma vaccine, V940 — the first of its kind to show real clinical benefit in a large Phase Three trial, outperforming standard care. Using mRNA tech to train the immune system alongside Keytruda, it’s designed to prevent cancer recurrence after surgery. The results sent Moderna’s stock soaring, sparking wild speculation about a potential short squeeze. While the data is promising, the trial isn’t complete — key outcomes like overall survival are still pending. This breakthrough could redefine cancer treatment and reignite investor confidence in mRNA innovation. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/4019c6e9b2515863

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.